$123.81
+6.69
(+5.71%)▲
Live
Insights on Sarepta Therapeutics, Inc.
Revenue is up for the last 4 quarters, 253.5M → 396.78M (in $), with an average increase of 13.5% per quarter
Netprofit is up for the last 2 quarters, -40.93M → 45.65M (in $), with an average increase of 189.7% per quarter
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 58.4%
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 182.3%
5.31%
Downside
Day's Volatility :6.27%
Upside
1.02%
55.38%
Downside
52 Weeks Volatility :65.44%
Upside
22.57%
Period | Sarepta Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -2.58% | 1.9% | 0.0% |
6 Months | 3.26% | 10.7% | 0.0% |
1 Year | -7.55% | 4.6% | -1.1% |
3 Years | 59.78% | 14.2% | -22.1% |
Market Capitalization | 10.9B |
Book Value | $9.17 |
Earnings Per Share (EPS) | -5.8 |
PEG Ratio | 159.25 |
Wall Street Target Price | 165.89 |
Profit Margin | -43.11% |
Operating Margin TTM | 6.21% |
Return On Assets TTM | -5.24% |
Return On Equity TTM | -86.15% |
Revenue TTM | 1.2B |
Revenue Per Share TTM | 13.46 |
Quarterly Revenue Growth YOY | 53.5% |
Gross Profit TTM | -78.1M |
EBITDA | -223.4M |
Diluted Eps TTM | -5.8 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 2.29 |
EPS Estimate Next Year | 10.55 |
EPS Estimate Current Quarter | 0.01 |
EPS Estimate Next Quarter | -0.3 |
What analysts predicted
Upside of 33.99%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 301.0M | ↑ 94.74% |
Net Income | -361.9M | ↑ 614.01% |
Net Profit Margin | -120.22% | ↓ 87.43% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 380.8M | ↑ 26.51% |
Net Income | -715.1M | ↑ 97.58% |
Net Profit Margin | -187.77% | ↓ 67.55% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 540.1M | ↑ 41.82% |
Net Income | -554.1M | ↓ 22.51% |
Net Profit Margin | -102.6% | ↑ 85.17% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 701.9M | ↑ 29.96% |
Net Income | -418.8M | ↓ 24.43% |
Net Profit Margin | -59.66% | ↑ 42.94% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 933.0M | ↑ 32.93% |
Net Income | -703.5M | ↑ 67.99% |
Net Profit Margin | -75.4% | ↓ 15.74% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 33.26% |
Net Income | -536.0M | ↓ 23.81% |
Net Profit Margin | -43.11% | ↑ 32.29% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 230.3M | ↓ 1.38% |
Net Income | -257.7M | ↑ 11.34% |
Net Profit Margin | -111.93% | ↓ 12.79% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 258.4M | ↑ 12.23% |
Net Income | -109.2M | ↓ 57.61% |
Net Profit Margin | -42.27% | ↑ 69.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 253.5M | ↓ 1.91% |
Net Income | -516.8M | ↑ 373.03% |
Net Profit Margin | -203.85% | ↓ 161.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 261.2M | ↑ 3.05% |
Net Income | -23.9M | ↓ 95.37% |
Net Profit Margin | -9.16% | ↑ 194.69% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 331.8M | ↑ 27.02% |
Net Income | -40.9M | ↑ 71.0% |
Net Profit Margin | -12.34% | ↓ 3.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 396.8M | ↑ 19.58% |
Net Income | 45.7M | ↓ 211.53% |
Net Profit Margin | 11.51% | ↑ 23.85% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 25.54% |
Total Liabilities | 609.8M | ↑ 17.55% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 11.01% |
Total Liabilities | 1.0B | ↑ 64.75% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.0B | ↑ 63.74% |
Total Liabilities | 2.2B | ↑ 121.27% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↑ 5.47% |
Total Liabilities | 2.2B | ↓ 0.13% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.62% |
Total Liabilities | 2.7B | ↑ 23.58% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.3B | ↑ 4.35% |
Total Liabilities | 2.4B | ↓ 12.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.2B | ↑ 5.32% |
Total Liabilities | 2.7B | ↑ 20.04% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.88% |
Total Liabilities | 2.7B | ↑ 0.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 2.19% |
Total Liabilities | 2.3B | ↓ 14.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↑ 2.16% |
Total Liabilities | 2.4B | ↑ 1.6% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.1B | ↓ 0.52% |
Total Liabilities | 2.3B | ↓ 1.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↑ 4.98% |
Total Liabilities | 2.4B | ↑ 2.55% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -388.7M | ↑ 67.53% |
Investing Cash Flow | -370.5M | ↑ 107.19% |
Financing Cash Flow | 530.2M | ↓ 40.3% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -456.5M | ↑ 17.45% |
Investing Cash Flow | 286.7M | ↓ 177.39% |
Financing Cash Flow | 642.6M | ↑ 21.2% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 107.5M | ↓ 123.54% |
Investing Cash Flow | -121.7M | ↓ 142.45% |
Financing Cash Flow | 682.3M | ↑ 6.19% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -443.2M | ↓ 512.38% |
Investing Cash Flow | 495.4M | ↓ 507.01% |
Financing Cash Flow | 561.6M | ↓ 17.7% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -325.3M | ↓ 26.59% |
Investing Cash Flow | -1.0B | ↓ 311.32% |
Financing Cash Flow | 232.5M | ↓ 58.6% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -65.0M | ↓ 2.77% |
Investing Cash Flow | 19.1M | ↓ 106.59% |
Financing Cash Flow | 216.4M | ↑ 63743.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -92.4M | ↑ 42.22% |
Investing Cash Flow | 9.8M | ↓ 48.76% |
Financing Cash Flow | 10.7M | ↓ 95.03% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -209.4M | ↑ 126.64% |
Investing Cash Flow | 12.5M | ↑ 27.52% |
Financing Cash Flow | 101.8M | ↑ 847.02% |
Sell
Neutral
Buy
Sarepta Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sarepta Therapeutics, Inc. | -8.46% | 3.26% | -7.55% | 59.78% | -0.88% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sarepta Therapeutics, Inc. | NA | NA | 159.25 | 2.29 | -0.86 | -0.05 | NA | 9.17 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sarepta Therapeutics, Inc. | Buy | $10.9B | -0.88% | NA | -43.11% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Vanguard Group Inc
BlackRock Inc
HHG PLC
Capital Research & Mgmt Co - Division 3
venBio Select Advisor LLC
Wellington Management Company LLP
Sarepta Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read Moresarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Organization | Sarepta Therapeutics, Inc. |
Employees | 1314 |
CEO | Mr. Douglas S. Ingram Esq. |
Industry | Health Technology |
Schwab Us Large-cap Growth Etf
$123.81
+5.71%
Union Pacific Corporation
$123.81
+5.71%
Molina Healthcare, Inc.
$123.81
+5.71%
Icici Bank Ltd.
$123.81
+5.71%
Globalfoundries Inc.
$123.81
+5.71%
Bunge Limited
$123.81
+5.71%
Lpl Financial Holdings Inc.
$123.81
+5.71%
Ares Capital Corporation
$123.81
+5.71%
Cognizant Technology Solutions Corp.
$123.81
+5.71%